Vaulx-en-Velin, France--High-intensity focused ultrasound (HIFU) appears to be a promising salvage therapy option in carefully selected recurrent prostate cancer patients who have previously undergone external beam radiation therapy. The device, which uses sound waves to target tumors, was found in a French study to stop disease progression in slightly more than 40% of patients at mean follow-up of 15 months.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.